医药制造企业是营销制胜还是研发制胜?  

Should pharmaceutical manufacturers win by marketing or by R&D?

作　　者：任海云[1] 谢秀翎 王博文 Ren Haiyun;Xie Xiuling;Wang Bowen(International Business School,Shaanxi Normal University,Xi′an 710119,Shaanxi,China)

机构地区：[1]陕西师范大学国际商学院,陕西西安710119

出　　处：《科研管理》2023年第8期78-88,共11页Science Research Management

基　　金：教育部人文社会科学研究规划基金:“基于企业技术创新异质性的政府补助政策效果评估与优化研究”(22YJA630067,2022.09—2025.09);陕西省软科学项目:“陕西省新能源汽车产业政府科技补助的效果评价及优化对策研究——基于‘强链补链’视角”(2022KRM108,2022.03—2024.02)。

摘　　要：我国医药制造企业普遍存在“重营销轻研发”现象,面对激烈的竞争、肆虐的病毒和不断调整的医改政策,医药制造企业究竟应该营销制胜还是研发制胜?以恒瑞医药和哈药股份两个典型企业为案例,采用纵向双案例对比研究法,按照时间序列对比不同营销和研发战略下的两个企业绩效差异,论证营销和研发如何影响企业绩效;并且引入“4+7”带量采购政策,对比政策实施后两个企业绩效的变化,说明不同营销和研发战略下的两个企业抗风险能力和绩效可持续性差异,以此进一步说明医药制造企业究竟营销制胜还是研发制胜。研究结果表明:医药制造企业应该营销研发双轮驱动才能行稳致远,带量采购政策实施后,医药制造企业一方面应该及时调整投资方向,注重研发创新,提高药品质量;另一方面应该积极参与集采保住市场,为研发创新提供持续资金支持。研究结论不仅丰富营销、研发与企业绩效关系的相关理论,而且为带量采购政策实施后企业进行投资决策提供有益借鉴。In the face of fierce competition,rampant viruses and constantly adjusted health care reform policies,should pharmaceutical manufacturers win through marketing or R&D?Taking two typical enterprises,Hengrui Medicine Co.,Ltd and Harbin Pharmaceutical Group Co.,Ltd,as cases,the author used the longitudinal double case comparison study method to list the typical matters in marketing and R&D in each development stage of the case enterprises according to the time series,compared the performance differences between the two enterprises under different marketing and R&D strategies,and demonstrated how marketing and R&D affect the enterprise performance.The study also introduced the"4+7"Volume Procurement Policy and compared the performance of the two companies after the implementation of the policy to illustrate the difference in risk resistance and performance sustainability between the two enterprises,so as to further illustrate whether pharmaceutical manufacturers should win by marketing or by R&D.The following conclusions were obtained from this research.Firstly,advertising and marketing can expand brand awareness of generic drugs in the short term,bring brand effect,increase the added value of generic drugs and improve corporate performance,but in the long term,without focusing on R&D and innovative drug output,marketing alone cannot ensure sustainable and stable corporate performance.Secondly,improving drug quality and forming high value-added innovative drugs through R&D innovation is conducive to improving enterprise gross margin and anti-risk ability,while the marketing and promotion of innovative drugs need high marketing expenses to support.Thirdly,R&D innovation can improve the quality of generic drugs,which is conducive to passing the consistency evaluation of drugs and entering centralized procurement,and the winning products can realize the quantity for price and keep the market share.Finally,the"4+7"Volume Procurement Policy can achieve real volume for price and failure to win the bid means to lose the mar

关 键 词：带量采购政策 研发 营销 医药制造企业 绩效 

分 类 号：F272.3[经济管理—企业管理]